David_Capper_297_x_337__383_.jpg

Prof. Dr. David Capper

Oberarzt

Charité – Universitätsmedizin Berlin
Institut für Neuropathologie
Charitéplatz 1
10117 Berlin

Campus- bzw. interne Geländeadresse:
Virchowweg 15

Sie befinden sich hier:

Inhaltsübersicht

Lebenslauf Prof. Dr. David Capper

 Education/Training

Education/ Training Institution

Year(s)

Degree

Otto Hahn Gymnasium, Nagold

1998

Baccalaureate

Medical School Tübingen, Germany

2000 - 2006

Medical degree "Approbation"

DFG Graduate College 686-1; University Tübingen, Germany

2003 - 2004 (12 months)

Scholarship for doctoral thesis

Doctoral thesis (Neuropathology Tübingen

2004 - 2008

Summa cum laude

 

Positions and Employment

Institution and Location

Year(s)

Position

Institute of Brain Research, Tübingen, Germany

2007 - 2007 (6 months)

Residency neuropathology

Department of Neuropathology, University Zurich, Switzerland

2007 – 2008 (12 months)

Residency neuropathology

Department of Neuropathology, University Heidelberg, Heidelberg

Since 2008

Residency neuropathology

Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ)

Bord certification Neuropathology

2010 - 2017

2013 - 2017

Non-compensation employee

Consultant Neuropathology University Hospital Heidelberg

Neuropathology Charite Berlin

German Cancer Consortium Berlin (DKTK), German Cancer Research Center (DKFZ)

Since April 2017

Since April 2017

Professor for Molecular Neuropathology

Faculty, Group leader molecular Neuropathology

Research Focus

Neuropathology, genetics and biology of adult and paediatric brain tumors. Biomarker development. Development of mutations specific antibodies. Clinical trial support (national and international). Implementation of DNA methylation signatures for tumor classification.

Honors

2008Summa cum laude for doctoral thesis (Eberhard-Karls-University Tübingen)
2012Werner-Rosenthal-prize of the Deutsche Gesellschaft für Neuropathologie und Neuroanatomie (DGNN Young Investigator Award; 1.000€)
2012Württembergischer Krebspreis der Dres. Bayerstiftung (Young Investigator Award,
10.000€)
2015Cavanagh Prize of the British Neuropathological Society (Young Investigator Award,
2.000€)
2018Curt Meyer Memorial award of the Berliner Krebsgesellschaft (10.000€)
2018Berlin Institute of Health (BIH) Quest open data award (1.000€)
2018

Innovation prize of the Deutschen Hochschulmedizin e.V. (10.000€)

Other Experience and Professional Memberships

  • cIMPACT: the consortium to inform molecular and practical approaches to CNS tumor
    taxonomy
  • Member of the “Consensus and Editorial Meeting Working Group” for the Update of the 4th
    edition of the WHO Classification of Tumours of the Central Nervous System
  • Member of the German Society for Neuropathology and Neuroanatomy (DGNN)

  • Member of the Society for Neuro-Oncology

Citations, h-Index, i10-index (08.2018)

 Name:

age

Articles

First / last authorship

Co-author

Total sum of citations

H Index

i10

Index

David Capper

39

163

17 first

10 last

136

6654

42

104

 Top 5 publications

  1. Capper D#, Jones, D T W.#, Sill, M#, Hovestadt, V#, [...] , von Deimling A*, Pfister, S M* DNA
    methylation-based classification of central nervous system tumours, Nature 2018. #Co-first
    authors *Co-last authors
  2. Worst BC#, van Tilburg CM#, Balasubramanian GP#, Fiesel P#, [...] , Capper D*, Pfister SM*,
    Jones DT*, Witt O*. Next-generation personalised medicine for high-risk paediatric cancer
    patients - The INFORM pilot study. Eur J Cancer. 2016 Sep;65:91-101. #Co-first authors * Co-last
    authors
  3. Schindler G, Capper D#, Meyer J, Janzarik W, Omran H, Herold-Mende C, Schmieder K,
    Wesseling P, Mawrin C, Hasselblatt M, Louis DN, Korshunov A, Pfister S, Hartmann C, Paulus W,
    Reifenberger G, von Deimling A: Analysis of BRAF V600E mutation in 1,320 nervous system
    tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and
    extra-cerebellar pilocytic astrocytoma, Acta Neuropathol 2011, 121:397-405. #Co-first authors
  4. Capper D, Weissert S, Balss J, Habel A, Meyer J, Jager D, Ackermann U, Tessmer C, Korshunov
    A, Zentgraf H, Hartmann C, von Deimling A: Characterization of R132H mutation-specific IDH1
    antibody binding in brain tumors, Brain Pathol 2010, 20:245-254.
  5. Capper D, Preusser M, Habel A, Sahm F, Ackermann U, Schindler G, Pusch S, Mechtersheimer
    G, Zentgraf H, von Deimling A: Assessment of BRAF V600E mutation status by
    immunohistochemistry with a mutation-specific monoclonal antibody, Acta Neuropathol. 2011
    Jul;122(1):11-9.


Scientific impact:
Dr. Cappers work has focussed on translational neuropathology form very early on. Focus of his work
was on a refined tumour classification and on the development of practice changing diagnostic
assays. The first attempts of this were by generating mutation specific antibodies against
neuropathologically relevant mutations (IDH1 R132H and BRAF V600E). Both of these tests have
become standard tests in worldwide pathological and neuropathological laboratories. In the last
years Dr. Capper focussed on implementation of high throughput molecular assays in clinical routine
either in a clinical translation trial setting (INFORM) or for daylily practice. This effort has led to the
recent generation of a DNA methylation based brain tumour classifier that is currently stepwise
entering diagnostic practice.


Dr. Capper was appointed as the youngest member of the "Consensus and Editorial Meeting Working
Group" of the 2016 WHO classification of brain tumors and is the youngest member of cIMPACT (the
consortium to inform molecular and practical approaches to CNS tumor taxonomy).

 

 

 



Vernetzung